AbbVie
Desconocido
PREFER: Patient Preferences in benefit risk assessments during the drug life cycle Sofia ref. 115966
AbbVie Ltd
participó en un
H2020:
H2020-JTI-IMI2-2015-05-two-stage
The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i....
2016-10-21 - 2022-05-31 | Financiado
2016-10-21 - 2022-05-31 | Financiado
ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach...
AbbVie Ltd
participó en un
H2020:
H2020-JTI-IMI2-2015-04-two-stage-Master
Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado
2015-09-02 - 2018-04-30 | Financiado
* No se disponen de datos de la empresa actual.